Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Orvig

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Chemical Society Reviews|February 9, 2016
Harnessing the bone-seeking ability of Ca(II)-like metal ions in the treatment of metastatic cancer and resorption disordersD M Weekes, C Orvig
Chemical Reviews|December 26, 2001
Medicinal inorganic chemistry: introductionC Orvig, M J Abrams
Clinical Chemistry|April 1, 1992
Complexation of iron with the orally active decorporation drug L1 (3-hydroxy-1,2-dimethyl-4-pyridinone)M A Kline, C Orvig
Inorganic Chemistry|July 10, 2001
Lanthanide chemistry with (bis[[bis(carboxymethyl)amino]methyl]phosphinate: what does an extra phosphinate group do to EDTA?L Xu, S J Rettig, C Orvig
Neurotoxicology and Teratology|June 25, 1998
Active oxygen species formation in synaptosomes exposed to an aluminum chelatorS C Bondy, H Tseng, C Orvig
Toxicology|April 12, 1995
Evidence for energy-dependent transport of aluminum out of brain extracellular fluidD D Allen, C Orvig, R A Yokel
Chemical Reviews|December 26, 2001
Vanadium compounds as insulin mimicsK H Thompson, J H McNeill, C Orvig
Canadian Journal of Physiology and Pharmacology|March 1, 1993
Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV)V G Yuen, C Orvig, J H McNeill
Canadian Journal of Physiology and Pharmacology|January 1, 1995
Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administrationV G Yuen, C Orvig, J H McNeill
Toxicology|September 6, 1994
Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapyD D Allen, C Orvig, R A Yokel
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Chemical Society Reviews|February 9, 2016
Harnessing the bone-seeking ability of Ca(II)-like metal ions in the treatment of metastatic cancer and resorption disordersD M Weekes, C Orvig
Chemical Reviews|December 26, 2001
Medicinal inorganic chemistry: introductionC Orvig, M J Abrams
Clinical Chemistry|April 1, 1992
Complexation of iron with the orally active decorporation drug L1 (3-hydroxy-1,2-dimethyl-4-pyridinone)M A Kline, C Orvig
Inorganic Chemistry|July 10, 2001
Lanthanide chemistry with (bis[[bis(carboxymethyl)amino]methyl]phosphinate: what does an extra phosphinate group do to EDTA?L Xu, S J Rettig, C Orvig
Neurotoxicology and Teratology|June 25, 1998
Active oxygen species formation in synaptosomes exposed to an aluminum chelatorS C Bondy, H Tseng, C Orvig
Toxicology|April 12, 1995
Evidence for energy-dependent transport of aluminum out of brain extracellular fluidD D Allen, C Orvig, R A Yokel
Chemical Reviews|December 26, 2001
Vanadium compounds as insulin mimicsK H Thompson, J H McNeill, C Orvig
Canadian Journal of Physiology and Pharmacology|March 1, 1993
Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV)V G Yuen, C Orvig, J H McNeill
Canadian Journal of Physiology and Pharmacology|January 1, 1995
Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administrationV G Yuen, C Orvig, J H McNeill
Toxicology|September 6, 1994
Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapyD D Allen, C Orvig, R A Yokel
Pageof 4